MedTech & Diagnostics

Baxter International Executive Compensation (FY25)

Name: Baxter International (BAX) executive compensation
Creator: Velarion
License: https://intel.velarion.ai/terms

BAX · Deerfield, IL · Executive and director compensation, fiscal 2022 to 2025

Chief executive, fiscal 2025

◇

Andrew Hider

Median of the other named officers

$5,242,744

8 officers, excluding the chief executive

Latest say-on-pay support

May 5, 2026

Chief executive pay ratio

◇

To the median employee

Velarion Member: every covered company in MedTech & Diagnostics, with dashboards, peer screens and board-ready briefs. Three seats, one year.

The paid brief on Baxter International

Positioning against its disclosed peers, the governance read, incentive design, and the CD&A alignment analysis; the full peer table; a committee-ready PDF.

From $499 for the board report; $2,400 for both.

Get the executive brief Get the board briefNo account needed.

Data as of October 22, 2026Latest filing (8-K): May 8, 2026

15 filings cited on this page

Method: intel.velarion.ai/methodology

A report that fails to generate is refunded in full

Published by Velarion Company Intelligence

Baxter International brief$1,500Get the executive brief

Velarion Member, one year

476 figures on this page: 465 cited to the filing that reported them, 11 calculated from figures it prints. See the citations

Frequently asked questions

Answers drawn from the data on this page.

Who is Baxter International's chief executive and what were they paid?

Andrew Hider was paid $29,805,182 in total compensation as President and CEO for fiscal 2025.

What was Baxter International's say-on-pay result?

Shareholders supported the say-on-pay proposal with 91.2% of votes cast for or against in favor at the meeting held May 5, 2026 for fiscal 2025.

Which companies are in Baxter International's peer group?

The disclosed peer group includes Abbott Laboratories, Agilent Technologies, Inc., Becton, Dickinson and Company, Boston Scientific Corporation and Danaher Corporation, among others.

What is Baxter International's chief executive pay ratio?

The company reported a chief executive pay ratio of 445:1 for fiscal 2025, against median employee compensation of $72,402.

Executive compensation

Every element reported for each named executive officer, by fiscal year.

Fiscal 2022

Officer	Salary	Bonus	Stock awards	Option awards	Non-equity incentive	Pension and deferred earnings	All other compensation	Total
José Almeida Chair, President and Chief Executive Officer	◇	—	◇	◇	◇	—	◇	◇
James Saccaro Executive Vice President and Chief Financial Officer	◇	—	◇	◇	◇	—	◇	◇
Giuseppe Accogli Executive Vice President and President, Hospital Products	◇	—	◇	◇	—	—	◇	◇
David Rosenbloom Senior Vice President and General Counsel	◇	—	◇	◇	◇	—	◇	◇
Cristiano Franzi Executive Vice President and President, Renal Care and Acute Therapies	◇	—	◇	◇	◇	—	◇	◇

Fiscal 2023

Officer	Salary	Bonus	Stock awards	Option awards	Non-equity incentive	Pension and deferred earnings	All other compensation	Total
José Almeida Chair of the Board, President and Chief Executive Officer	◇	—	◇	◇	◇	—	◇	◇
Christopher Toth Executive Vice President and Group President, Kidney Care	◇	◇	◇	—	◇	—	◇	◇
Cristiano Franzi Former Senior Vice President and President, EMEA Departed during or after this year	◇	—	◇	◇	◇	—	◇	◇
Joel Grade Executive Vice President and Chief Financial Officer	◇	—	◇	◇	◇	—	◇	◇
Heather Knight Executive Vice President and Group President, Medical Products & Therapies Served on an interim basis	◇	—	◇	◇	◇	—	◇	◇
Alok Sonig Executive Vice President and Group President, Pharmaceuticals	◇	—	◇	◇	◇	—	◇	◇
James Saccaro Former Executive Vice President and Chief Financial Officer Departed during or after this year	◇	—	◇	◇	—	—	◇	◇
Brian Stevens Senior Vice President, Chief Accounting Officer & Controller and Former Interim Chief Financial Officer	◇	◇	◇	◇	◇	—	◇	◇

Fiscal 2024

Officer	Salary	Bonus	Stock awards	Option awards	Non-equity incentive	Pension and deferred earnings	All other compensation	Total
José Almeida Former Chair of the Board, President and Chief Executive Officer Departed during or after this year	◇	—	◇	—	◇	—	◇	◇
Christopher Toth Former Executive Vice President and Group President, Kidney Care Departed during or after this year	◇	—	◇	—	◇	—	◇	◇
Heather Knight Executive Vice President, Chief Operating Officer and Interim Group President, Medical Products & Therapies Served on an interim basis	◇	—	◇	—	◇	—	◇	◇
Joel Grade Executive Vice President and Chief Financial Officer	◇	◇	◇	—	◇	—	◇	◇
Alok Sonig Executive Vice President and Group President, Pharmaceuticals	◇	—	◇	—	◇	—	◇	◇

Fiscal 2025

Officer	Salary	Bonus	Stock awards	Option awards	Non-equity incentive	Pension and deferred earnings	All other compensation	Total
Andrew Hider President and CEO	◇	◇	◇	◇	◇	—	◇	◇
Joel Grade Former Executive Vice President and CFO Departed during or after this year	◇	—	◇	◇	◇	—	◇	◇
José Almeida Former Chair of the Board, President and CEO Departed during or after this year	◇	—	—	—	—	—	◇	◇
Heather Knight Former Executive Vice President, COO and Interim Group President, Medical Products & Therapies Departed during or after this year Served on an interim basis	◇	—	◇	◇	—	—	◇	◇
Reazur Rasul Executive Vice President and Group President, Healthcare Systems & Technologies	◇	—	◇	◇	◇	—	◇	◇
Alok Sonig Former Executive Vice President and Group President, Pharmaceuticals Departed during or after this year	◇	—	◇	◇	—	—	◇	◇
Brent Shafer Non-Executive Chair and Former Executive Chair and Interim CEO Departed during or after this year Served on an interim basis	◇	◇	◇	—	—	—	◇	◇
David Rosenbloom Executive Vice President and General Counsel	◇	—	◇	◇	◇	—	◇	◇
Cecilia Soriano Group President, Infusion Therapies & Technologies and Pharmaceuticals	◇	◇	◇	◇	◇	—	◇	◇

A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero. A negative change in pension value is shown but, as the company reports it, not included in the total.

Equity awards granted

Individual awards as disclosed: type, date, unit counts at each level, and grant date value.

Fiscal 2025

Officer	Award	Grant date	Threshold units	Target units	Units granted	Maximum units	Exercise price	Grant date fair value
Andrew Hider	RSU	◇	—	—	◇	—	—	◇
Andrew Hider	RSU	◇	—	—	◇	—	—	◇
Andrew Hider	OPTION	◇	—	—	◇	—	◇	◇
Andrew Hider	PSU	◇	◇	◇	—	◇	—	◇
Andrew Hider	PSU	◇	◇	◇	—	◇	—	◇
Andrew Hider	PSU	◇	◇	◇	—	◇	—	◇
Brent Shafer	RSU	◇	—	—	◇	—	—	◇
Heather Knight	OPTION	◇	—	—	◇	—	◇	◇
Heather Knight	PSU	◇	◇	◇	—	◇	—	◇
Heather Knight	RSU	◇	—	—	◇	—	—	◇
Joel Grade	RSU	◇	—	—	◇	—	—	◇
Joel Grade	PSU	◇	◇	◇	—	◇	—	◇
Joel Grade	RSU	◇	—	—	◇	—	—	◇
Joel Grade	OPTION	◇	—	—	◇	—	◇	◇
Reazur Rasul	RSU	◇	—	—	◇	—	—	◇
Reazur Rasul	PSU	◇	◇	◇	—	◇	—	◇
Reazur Rasul	OPTION	◇	—	—	◇	—	◇	◇

Fiscal 2022, 2023 are included in the PDF.

A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero. Threshold, target and maximum apply only to performance awards and are never shown for time-based or option awards.

Outstanding awards

Awards still held at fiscal year end.

As disclosed at fiscal 2025 year end

Officer	Award	Unvested units	Market value of unvested units	Exercise price	Expires
Reazur Rasul	Option	◇	—	◇	3/6/2035
	RSU	◇	◇	—	—
	RSU	◇	◇	—	—
	RSU	◇	◇	—	—
	RSU	◇	◇	—	—
	Option	◇	—	◇	3/1/2027
	Option	◇	—	◇	3/2/2027
	Option	◇	—	◇	3/1/2028
	Option	◇	—	◇	2/28/2029
	Option	◇	—	◇	3/20/2030
	Option	◇	—	◇	3/3/2031
	Option	◇	—	◇	3/2/2032
	Option	◇	—	◇	3/1/2033
David Rosenbloom	RSU	◇	◇	—	—
	RSU	◇	◇	—	—
	RSU	◇	◇	—	—
	RSU	◇	◇	—	—
	RSU	◇	◇	—	—
	Option	◇	—	◇	3/6/2035
	Option	◇	—	◇	6/1/2032
	Option	◇	—	◇	3/1/2033
Andrew Hider	RSU	◇	◇	—	—
	RSU	◇	◇	—	—
	RSU	◇	◇	—	—
	RSU	◇	◇	—	—
	Option	◇	—	◇	9/2/2035
Joel Grade	RSU	◇	◇	—	—
	RSU	◇	◇	—	—
	RSU	◇	◇	—	—
	RSU	◇	◇	—	—
	RSU	◇	◇	—	—
	RSU	◇	◇	—	—
	RSU	◇	◇	—	—
	RSU	◇	◇	—	—
	Option	◇	—	◇	12/1/2033
	Option	◇	—	◇	3/6/2035
Jos Almeida	RSU	◇	◇	—	—
	RSU	◇	◇	—	—
	RSU	◇	◇	—	—
	Option	◇	—	◇	3/1/2028
	Option	◇	—	◇	10/31/2030
	RSU	◇	◇	—	—
	Option	◇	—	◇	3/2/2027
	Option	◇	—	◇	3/20/2030
	Option	◇	—	◇	2/28/2029
	Option	◇	—	◇	10/31/2030
	Option	◇	—	◇	10/31/2030
Maria Soriano	RSU	◇	◇	—	—
	RSU	◇	◇	—	—
	RSU	◇	◇	—	—
	RSU	◇	◇	—	—
	RSU	◇	◇	—	—
	Option	◇	—	◇	3/1/2033
	Option	◇	—	◇	3/6/2035
Heather Knight	Option	◇	—	◇	1/27/2026
	Option	◇	—	◇	1/27/2026
	Option	◇	—	◇	1/27/2026
	Option	◇	—	◇	1/27/2026
	Option	◇	—	◇	1/27/2026
	Option	◇	—	◇	1/27/2026
Alok Sonig	Option	◇	—	◇	3/1/2026
	Option	◇	—	◇	3/1/2026

A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.

Severance and change in control

The terms as written in the agreements.

Alok Sonig

Former Executive Vice President and Group President, Pharmaceuticals · Terms as described in the company’s compensation discussion · citing a 2026 filing

Severance multiple	◇
Change-in-control multiple	◇
Benefits continuation on change in control	◇
Benefits continuation	◇
Non-compete period	◇
Non-solicit period	◇

Andrew Hider

President and CEO · Terms as described in the company’s compensation discussion · citing a 2026 filing

Severance multiple	◇
Change-in-control multiple	◇
Benefits continuation on change in control	◇
Benefits continuation	◇
Excise tax treatment	◇
Non-compete period	◇
Non-solicit period	◇

David Rosenbloom

Executive Vice President and General Counsel · Terms as described in the company’s compensation discussion · citing a 2026 filing

Severance multiple	◇
Severance cash amount	◇
Change-in-control multiple	◇
Benefits continuation on change in control	◇
Benefits continuation	◇
Non-compete period	◇
Non-solicit period	◇

Heather Knight

Former Executive Vice President, COO and Interim Group President, Medical Products & Therapies · Terms as described in the company’s compensation discussion · citing a 2026 filing

Severance multiple	◇
Change-in-control multiple	◇
Benefits continuation on change in control	◇
Benefits continuation	◇
Non-compete period	◇
Non-solicit period	◇

Joel Grade

Former Executive Vice President and CFO · Terms as described in the company’s compensation discussion · citing a 2026 filing

Severance multiple	◇
Severance cash amount	◇
Change-in-control multiple	◇
Benefits continuation on change in control	◇
Benefits continuation	◇
Non-compete period	◇
Non-solicit period	◇
Clawback	◇

Reazur Rasul

Executive Vice President and Group President, Healthcare Systems & Technologies · Terms as described in the company’s compensation discussion · citing a 2026 filing

Severance multiple	◇
Severance cash amount	◇
Change-in-control multiple	◇
Benefits continuation on change in control	◇
Benefits continuation	◇
Non-compete period	◇
Non-solicit period	◇

Director compensation

What each non-employee director was paid.

Fiscal 2025

Director	Fees earned in cash	Stock awards	Option awards	Non-equity incentive	Pension and deferred earnings	All other compensation	Total
Nancy M. Schlichting	◇	◇	—	—	—	◇	◇
Stephen N. Oesterle	◇	◇	—	—	—	◇	◇
David S. Wilkes	◇	◇	—	—	—	◇	◇
Cathy R. Smith	◇	◇	—	—	—	—	◇
Patricia B. Morrison	◇	◇	—	—	—	◇	◇
Jeffrey A. Craig	◇	◇	—	—	—	—	◇
Amy A. Wendell	◇	◇	—	—	—	◇	◇
Stephen H. Rusckowski	◇	◇	—	—	—	◇	◇
William A. Ampofo II	◇	◇	—	—	—	◇	◇
Brent Shafer Board chair	◇	—	—	—	—	—	◇

Michael R. McDonnell served on the board in fiscal 2025 and received no compensation for board service. Executive directors are typically paid through their executive roles, shown above.

Earlier years are included in the PDF.

A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.

Director fee schedule

The standing retainers and premiums the board pays, as published.

Board cash retainer	◇
Board equity retainer	◇
Total board retainer	◇
Board chair premium	◇
Lead independent director premium	◇
Audit committee chair	◇
Compensation committee chair	◇
Nominating and governance chair	◇

Equity is delivered as Stock.

Disclosed peer group

The companies this board named as its compensation comparison group. The list is disclosure; the comparison is analysis.

Fiscal 2025

Abbott Laboratories ABT
Agilent Technologies, Inc. A
Becton, Dickinson and Company BDX
Boston Scientific Corporation BSX
Danaher Corporation DHR
DaVita Inc. DVA
DENTSPLY Sirona Inc. XRAY
Edwards Lifesciences EW
GE HealthCare Technologies GEHC
Hologic, Inc. HOLX
Intuitive Surgical, Inc. ISRG
Laboratory Corporation of America Holdings LH
Medtronic Public Limited Company MDT
Quest Diagnostics Incorporated DGX
Stryker Corporation SYK
Zimmer Biomet Holdings, Inc. ZBH

Say-on-pay history

Shareholder support for the compensation program, by year.

Year	Meeting	Support	Votes for	Votes against	Abstentions
2025	May 5, 2026	=	◇	◇	◇
2024	May 6, 2025	=	◇	◇	◇
2023	May 7, 2024	=	◇	◇	◇
2022	May 2, 2023	=	◇	◇	◇
2021	May 3, 2022	=	◇	◇	◇
2020	May 4, 2021	=	◇	◇	◇
2019	May 5, 2020	=	◇	◇	◇
2018	May 7, 2019	=	◇	◇	◇
2017	May 8, 2018	=	◇	◇	◇
2016	May 2, 2017	=	◇	◇	◇
2015	May 3, 2016	=	◇	◇	◇

Chief executive pay ratio

As calculated and reported by the company.

Ratio

◇

Median employee compensation

◇

Chief executive total compensation

◇

Velarion Pro: every company page, peer tools and exports, one seat

One seat, one person. It opens the whole platform: the peer tools, the written analysis and the exports, on every company we cover. Join the list and you will hear from us when it opens.

Ask our research desk — $99, 24h, every figure cited to its filing.

Sample answer — “What is the CEO’s total compensation?”

- Andrew Hider (President and CEO), FY2025 total compensation $29,805,182 (base salary $499,315) [exec_comp, SEC accession 0001628280-26-020330, filed 2026-03-23]

What this page does not include

Everything above is a fact Baxter International disclosed, and it is free. Everything below is our analysis of those facts, and it is not.

Peer benchmarking

Where Baxter International sits against its disclosed peers — percentile position by role and by pay element, and the ranking behind it. The disclosed peer group is free; comparisons across it are part of the Velarion platform.

Executive Compensation Report — $1,500

Written compensation analysis

A read of the pay program as designed and as paid: incentive structure, goal rigor, the alignment between the committee's stated philosophy and what the numbers show.

Executive Compensation Report — $1,500

Board and governance analysis

Committee composition, independence, director pay positioning, and the governance provisions read together rather than listed.

Board Governance Report — $499

Realizable pay

What the awards above are actually worth today against what they were valued at on grant, and what the gap says about the pay-for-performance link.

Velarion Intelligence

Adviser switching and vote outcomes

Two datasets covering compensation-adviser changes and what followed a contested vote. Both are part of the Velarion platform.

Inquire about access

Multiple companies at once

Cross-company views, cohort screens, and data export across the industries we cover. This page is one company; the platform is all of them.

Velarion Intelligence

Citations

Every figure on this page is cited to the document that reported it. Select any figure to see its citation.

476 figures on this page: 465 cited to the filing that reported them, 11 calculated from figures it prints.

465 cited to the filing

11 calculated from the filing

Documents cited

8-K, filed May 8, 2026
0001193125-26-214680
Item 5.07 Submission of Matters to a Vote of Security Holders.
DEF 14A, filed March 23, 2026
0001628280-26-020330
CEO Pay Ratio · Compensation Discussion and Analysis · Director Compensation · Grants of Plan-Based Awards · and 2 more sections
8-K, filed May 8, 2025
0001628280-25-023809
Item 5.07 Submission of Matters to a Vote of Security Holders
DEF 14A, filed March 25, 2025
0001628280-25-014747
2024 Summary Compensation Table
8-K, filed May 9, 2024
0001628280-24-022267
Item 5.07 Submission of Matters to a Vote of Security Holders
DEF 14A, filed March 25, 2024
0001193125-24-075975
2023 Summary Compensation Table
8-K, filed May 4, 2023
0001628280-23-015793
DEF 14A, filed March 23, 2023
0001193125-23-077304
2022 Summary Compensation Table
8-K, filed May 6, 2022
0001193125-22-143745
8-K, filed May 5, 2021
0001193125-21-151879
8-K, filed May 8, 2020
0001193125-20-137671
8-K, filed May 10, 2019
0001193125-19-143553
8-K, filed May 10, 2018
0001193125-18-159373
8-K, filed May 4, 2017
0001193125-17-158934
Item 5.07 Submission of Matters to a Vote of Security Holders
8-K, filed May 4, 2016
0001193125-16-577979

Cite this data

This page is free to cite. Attribution we ask for:

Velarion, “Baxter International executive compensation, FY2022–FY2025.” https://intel.velarion.ai/comp/BAX (accessed 2026).

Short form: data: Velarion

The paid brief for Baxter International

Positioning against its disclosed peers, the governance read, incentive design, and the CD&A alignment analysis; the full peer table; a committee-ready PDF.

From $499 for the board report; $2,400 for both.

Get the executive brief Get the board briefNo account needed.

15 filings cited on this page

Method: intel.velarion.ai/methodology

A report that fails to generate is refunded in full

Published by Velarion Company Intelligence

Embed this data

A small, cited view of this data for your own page or newsletter. Every embed carries a visible link back here, so the attribution travels with it.

The headline figures, each with its citation.

<iframe src="https://intel.velarion.ai/comp/BAX/embed" width="560" height="480" style="border:1px solid #d8dee8;border-radius:10px" loading="lazy" title="Baxter International executive compensation, from Velarion"></iframe>

Connect an AI assistant

Ask your own assistant about Baxter International and roughly 3,000 other US public companies, and get back the same figures on this page with the same citations. Free read access, no account. Add this to your assistant's connector settings.

{
  "mcpServers": {
    "velarion": {
      "type": "http",
      "url": "https://api.velarion.ai/mcp"
    }
  }
}

Setup guide and the full list of questions it answers

MedTech & Diagnostics rankings

Chief executive pay — MedTech & Diagnostics CEO pay ratio — MedTech & Diagnostics Say-on-pay support — MedTech & Diagnostics

Peers Baxter International discloses

The companies named in BAX's own disclosed peer group.

Abbott Laboratories Agilent Technologies, Inc.Becton, Dickinson and Company Boston Scientific Corporation Danaher Corporation DaVita Inc.DENTSPLY Sirona Inc.Edwards Lifesciences GE HealthCare Technologies Hologic, Inc.Intuitive Surgical, Inc.Laboratory Corporation of America Holdings Medtronic Public Limited Company Quest Diagnostics Incorporated Stryker Corporation Zimmer Biomet Holdings, Inc.

Terms on this page

Say-on-Pay Vote CEO Pay Ratio Median Employee Compensation All companies

Free to read and cite. Redistribution or bulk use of the dataset requires a data license. Talk to us about the data license.

Cite this data

APA

Velarion Company Intelligence. (2026). Velarion database: executive and board compensation data (Version 2026Q3) [Data set]. Zenodo. https://doi.org/10.5281/zenodo.22283854

BibTeX

@misc{velarionData2026,
  author = {{Velarion Company Intelligence}},
  title = {Velarion database: executive and board compensation data},
  year = {2026},
  version = {2026Q3},
  doi = {10.5281/zenodo.22283854},
  publisher = {Zenodo},
  url = {https://doi.org/10.5281/zenodo.22283854}
}

More on Baxter International

Frequently asked questions

Executive compensation

Equity awards granted

Outstanding awards

Severance and change in control

Director compensation

Director fee schedule

Disclosed peer group

Say-on-pay history

Chief executive pay ratio

Velarion Pro: every company page, peer tools and exports, one seat

What this page does not include

Citations

Documents cited

The paid brief for Baxter International

MedTech & Diagnostics rankings

Peers Baxter International discloses

Terms on this page